"10.1371_journal.pone.0113918","plos one","2014-12-03T00:00:00Z","Diana Marcela Penarete-Vargas; Anaïs Boisson; Serge Urbach; Hervé Chantelauze; Suzanne Peyrottes; Laurent Fraisse; Henri J Vial","Dynamique des Interactions Membranaires Normales et Pathologiques, CNRS UMR 5235, Université Montpellier II, cc107, Place Eugène Bataillon, 34095 Montpellier Cedex 05, France; Institut de Génomique Fonctionnelle, CNRS UMR 5203, INSERM U661, Université Montpellier I, Université Montpellier II, F-34094 Montpellier, France; Institut des Biomolécules Max Mousseron, CNRS UMR 5247, Université Montpellier II, cc1705, Place Eugène Bataillon, 34095 Montpellier Cedex 05, France; Sanofi, Therapeutic Strategic Unit for Infectious Diseases, 195 route dEspagne, BP 13669, 31036 Toulouse Cedex, France","Conceived and designed the experiments: DMPV SP HJV. Performed the experiments: DMPV AB SU HC. Analyzed the data: DMPV SU HJV. Contributed reagents/materials/analysis tools: LF. Wrote the paper: DMPV HJV.","The authors have declared that no competing interest exists with the commercial funders of this research study (Sanofi). The authors declare that DMPV and LF received salaries from the funder. For the purpose of transparency, the authors also declare that the patent number WO200105742 was submitted by CNRS and partly licensed to Sanofi and that the pharmaceutical product albitiazolium is currently under clinical development operated by the funder. All the authors confirm that this does not alter their adherence to PLOS ONE policies on sharing data and materials.","2014","12","Diana Marcela Penarete-Vargas","DMPV",7,FALSE,3,4,3,2,TRUE,TRUE,FALSE,0,NA,FALSE
